28 results
8-K
EX-99.1
APGE
Apogee Therapeutics, Inc.
19 Aug 24
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025
7:29am
-in-class efficacy and dosing. This approach underscores our relentless pursuit for the next wave of innovation in treating patients with AD. We refuse
DEF 14A
bikmdq7bjv jpui2tw9
24 Apr 24
Definitive proxy
4:15pm
424B4
ngg0 htgctf99c
11 Mar 24
Prospectus supplement with pricing info
6:01am
10-K
723y jj2wjk
5 Mar 24
Annual report
6:15am
DRS
hpj4j
9 Feb 24
Draft registration statement
12:00am
10-Q
qr0mr4qzf tv
28 Aug 23
Quarterly report
8:00am
10-Q
EX-10.2
sjlzx
28 Aug 23
Quarterly report
8:00am
10-Q
EX-4.2
eue tkouue6c
28 Aug 23
Quarterly report
8:00am
10-Q
EX-2.1
iw0kfx9
28 Aug 23
Quarterly report
8:00am
10-Q
EX-10.3
86ytg9o3c481wmncd
28 Aug 23
Quarterly report
8:00am
10-Q
EX-10.4
rv0b5so
28 Aug 23
Quarterly report
8:00am
8-K
EX-99.1
5u9dgt375 lm1
21 Aug 23
Departure of Directors or Certain Officers
7:35am
424B4
yjnhqk c9c63rtkq0
17 Jul 23
Prospectus supplement with pricing info
4:08pm